Testing new drugs to help people with alcohol use disorder
Preclinical validation of mGlu2 PAMs in alcohol use disorder
This study is looking at new medications that might help people with alcohol use disorder by improving how their brains work after drinking, and it aims to find better ways to support those trying to reduce their alcohol use and avoid relapse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Camino Pharma, LLC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-10932992 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of new compounds that target specific brain receptors to help reduce alcohol dependence and prevent relapse in individuals with alcohol use disorder (AUD). The study focuses on understanding how these compounds can normalize brain activity disrupted by chronic alcohol use. By examining the effects of these drugs on brain regions involved in alcohol-related behaviors, the research aims to develop better treatment options for those struggling with AUD. Participants may be involved in assessments that evaluate their response to these new therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are struggling with alcohol use disorder.
Not a fit: Patients who are not experiencing alcohol use disorder or are under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and better-tolerated treatments for individuals with alcohol use disorder.
How similar studies have performed: Previous research has shown promise in targeting glutamate receptors for treating substance use disorders, indicating potential for success in this approach.
Where this research is happening
San Diego, United States
- Camino Pharma, LLC — San Diego, United States (Active)
Researchers
- Principal investigator: Gadient, Reto Andreas — Camino Pharma, LLC
- Study coordinator: Gadient, Reto Andreas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.